HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results

Abstract : We examine whether a firm’s decision to disclose non-financial proprietary information depends on peer disclosures of similar information. Using a sample of 5,035 unique clinical trials by U.S. pharmaceutical firms over the 2007-2014 period, we find that the firm is less likely to disclose its own clinical trial results if peers have published clinical trial results pertaining to the same medical condition. Conditional on disclosing clinical trial results, the firm is also less likely to disclose the trial results on time when peers have disclosed their clinical trial results. Our cross-sectional tests suggest that proprietary costs of disclosure play an important role in the relation between peer disclosures and the firm’s own disclosure. In particular, the negative relation is more pronounced when proprietary costs of disclosure are higher. Taken together, our findings provide new evidence on the interplay between peer and own disclosures of non-financial proprietary information.
Document type :
Preprints, Working Papers, ...
Complete list of metadata

Contributor : Antoine Haldemann Connect in order to contact the contributor
Submitted on : Friday, July 10, 2020 - 12:11:53 PM
Last modification on : Tuesday, January 4, 2022 - 6:05:31 AM

Links full text



Vedran Capkun, Yun Lou, Yin Wang. Do Firms Respond to Peer Disclosures? Evidence from Disclosures of Clinical Trial Results. 2020. ⟨hal-02896056⟩



Record views